| |
Hi Jay:
This is for identification:
"CONTRIBUTING EDITOR APPOINTED FOR MED-TECH 2000 - Jay Abella, a
regulatory and project management specialist engaged in providing clinical and pre-clinical/toxicology services to biopharmaceutical and medical device companies, joins Westergaard Online today as Editor of "Westergaard Abella MED-TECH 2000." He succeeds Emile Westergaard who has joined the health care services group at Bear Stearns. Publication
of MED-TECH 2000 will resume next week. A 1989 graduate of Middlebury College, Abella holds an MBA and an MHA (Masters in Heatlhcare Admininistration) from the University of North Carolina. He will maintain cyber-residence in Raleigh, NC."
If you go trough my posts on SI, you will quickly find who am I!!
If somebody do not know:
Miljenko Zuanic, PhD, [Croatia, Europe]
1170 West 22nd Street, San Pedro, CA 90731
310-8330614
I have few question for you:
1. Who was doing clinical Phase III study for BDNF on behalf of the amgn-regn partnership?
2. Who was independent investigator-double blind study?
3. Who receive and when note/results from study?
4. Was the MED-TECH involved in BDNF ALS study?
5. If yes, what was involvement?
6. WHO GIVE INFORMATION TO SB ANALYST [MR. R. LANSTRA] FOUR WEEKS AHEAD OF NEWS ANNOUNCEMENT?
" a. On 11/15/96 Mr. Lanstra recommend strong buy for regn.
b. On 12/13/96 he downgrade to hold/bay.
c. On 12/17/96 he recommend strong buy for amgn."
7. Analysis of data (on 1/10/97) was not completed. Regn in 10K stated that some group in trials has positive outcome and it is considering new phase III trials for BDNF-SUBCATANEOUS!!!
Mr. Jay, I will suggest that you do your work professionally as you are obligated by yours position. Fishing on SI (bathtub) you can catch "cold". Tried deep see-water (amgn, regn, investigator, clinical setting, service provider,...) and we can all eat big "fish".
I am still down 25% on REGN, and will love that somebody responsible for scam pay for it.
Good luck in research.
regards,
mz |
|
